171485-39-5
Chemical Structure
Myrislignan
- CAS No.: 171485-39-5
- Formula:C21H26O6
- Molecular Weight:374.43
IUPAC Name: 4-((1R,2S)-2-(4-allyl-2,6-dimethoxyphenoxy)-1-hydroxypropyl)-2-methoxyphenol
InChIKey: ULZFTGWWPHYLGI-RBZFPXEDSA-N
SMILES: C[C@@H]([C@@H](C1=CC(OC)=C(O)C=C1)O)OC(C(OC)=CC(CC=C)=C2)=C2OC
Biological Activity: Myrislignan is a PI3K/AKT/NF-κB inhibitor that can cross the blood-brain barrier. Myrislignan exerts anticancer activity by inducing apoptosis and ferroptosis. Myrislignan inhibits the replication and invasion of Toxoplasma gondii; it induces reactive oxygen species (ROS) imbalance, autophagy, and the death of Toxoplasma gondii tachyzoites. Myrislignan inhibits mitochondrial function and ERK1/2 phosphorylation to improve ovariectomy-induced osteoporosis. Myrislignan can be used in studies related to gastric cancer, glioblastoma, osteoporosis, and toxoplasmosis[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Myrislignan | 99.53% | Myrislignan is a PI3K/AKT/NF-κB inhibitor that can cross the blood-brain barrier. Myrislignan exerts anticancer activity by inducing apoptosis and ferroptosis. Myrislignan inhibits the replication and invasion of Toxoplasma gondii; it induces reactive oxygen species (ROS) imbalance, autophagy, and the death of Toxoplasma gondii tachyzoites. Myrislignan inhibits mitochondrial function and ERK1/2 phosphorylation to improve ovariectomy-induced osteoporosis. Myrislignan can be used in studies related to gastric cancer, glioblastoma, osteoporosis, and toxoplasmosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Myrislignan-13C,d2 | Myrislignan-13C,d2 is the 13C, d2 deuterated-labeled Myrislignan (HY-N0608). Myrislignan is a PI3K/AKT/NF-κB inhibitor that can cross the blood-brain barrier. Myrislignan exerts anticancer activity by inducing apoptosis and ferroptosis. Myrislignan inhibits the replication and invasion of Toxoplasma gondii; it induces reactive oxygen species (ROS) imbalance, autophagy, and the death of Toxoplasma gondii tachyzoites. Myrislignan inhibits mitochondrial function and ERK1/2 phosphorylation to improve ovariectomy-induced osteoporosis. Myrislignan can be used in studies related to gastric cancer, glioblastoma, osteoporosis, and toxoplasmosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
-
[1]. Zhou YJ, et al. Myrislignan Induces Apoptosis in Gastric Cancer Cell Line Through PI3K/AKT Signaling Pathway. Sichuan Da Xue Xue Bao Yi Xue Ban. 2023 Jan;54(1):136-141. Chinese.
[Content Brief] - [2]. Zhou Y, et al. NF-B Inhibitor Myrislignan Induces Ferroptosis of Glioblastoma Cells via Regulating Epithelial-Mesenchymal Transformation in a Slug-Dependent Manner. Oxidative medicine and cellular longevity. 2023;2023:7098313. [Content Brief]
- [3]. Yang T, et al. Myrislignan targets extracellular signal-regulated kinase (ERK) and modulates mitochondrial function to dampen osteoclastogenesis and ovariectomy-induced osteoporosis. Journal of translational medicine. 2023 Nov 22;21(1):839. [Content Brief]
-
[4]. Zhang J, et al. Myrislignan Induces Redox Imbalance and Activates Autophagy in Toxoplasma gondii. Front Cell Infect Microbiol. 2021 Sep 3;11:730222.
[Content Brief]
